NCT03783923终止3 期
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 18
- 主要终点
- Change From Baseline in Time to Climb 4 Stairs After 26 Weeks of Treatment With Deflazacort
研究概览
简要总结
This study is designed to evaluate the safety and efficacy of deflazacort in participants with LGMD2I. Most participants enrolled will have a screening visit and 3 additional visits (after 1, 13, and 26 weeks of treatment).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Genetic diagnosis of LGMD2I (confirmed mutation in the fukutin-related protein [FKRP] gene).
- •Ability to ascend 4 stairs greater than or equal to (≥) 2.5 seconds and be able to complete the ascent and descent both at screening and baseline.
- •Ability to understand the nature of the study and the consent form and to comply with study related procedures.
- •Must weigh between 35 to 112.5 kilograms (kg).
排除标准
- •Received ≥4 weeks of continuous, systemic corticosteroid therapy within 3 months of study screening visit.
- •Presence of significant cardiomyopathy as defined by echocardiogram (left ventricular ejection fraction less than (<) 30 percent [%]) at screening.
- •Requires fulltime ventilator support.
- •History of chronic systemic fungal or viral infections.
- •History of recent bacterial infection (including tuberculosis) per discretion of the Investigator.
- •Diagnosis of diabetes mellitus (controlled and/or uncontrolled) defined as glycated hemoglobin (HbA1c) ≥6.5% (based on historical or present diagnosis).
- •History of immunosuppression or other contraindications to glucocorticosteroid therapy.
- •Requires concomitant use or greater than (>) 1 week of drugs or substances that are moderate to strong cytochrome P3A4 (CYP3A4) inhibitors (for example, clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) or moderate or strong CYP3A4 inducers (that is, rifampin, efavirenz, carbamazepine, phenytoin) at baseline.
- •Participated in an interventional clinical trial within the last 3 months prior the baseline visit.
- •Unable or unwilling to comply with the contraceptive requirements of the protocol.
- •Female participants who are pregnant and/or breastfeeding.
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, psychiatric, or allergic disease.
研究组 & 干预措施
Deflazacort
Experimental
Participants will receive deflazacort 0.6 milligrams per kilograms per day (mg/kg/day) orally. The dose could be reduced in case of tolerability issues. Any participant assigned to placebo prior to the Version 4.0 amendment (prior to or after 01 February 2020) will have the option to be consented under Version 4.0 and will be switched to deflazacort for 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (prior to 01 February 2020) will have the option to re-consent under Protocol Version 4.0 and continue for an additional 26 weeks treatment. Any participant assigned to deflazacort prior to the Version 4.0 amendment (after 01 February 2020) will have the option to re-consent under Protocol Version 4.0 at their Week 13 Visit and continue treatment until Week 26. Any new participant enrolled until 31 May 2020 will receive deflazacort for 26 weeks.
干预措施: Deflazacort (Drug)
结局指标
主要结局
Change From Baseline in Time to Climb 4 Stairs After 26 Weeks of Treatment With Deflazacort
时间窗: Baseline, Week 26
次要结局
- Change From Baseline in Forced Vital Capacity (FVC) After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in 2-Minute Walk Test After 26 Weeks of Treatment of Deflazacort(Baseline, Week 26)
- Change From Baseline in Time to up and go After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in Time to Descend 4 Stairs After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in Time to Run/Walk 10 Meters After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in Maximal Inspiratory Pressure (MIP) and Maximal Expiratory Pressure (MEP) After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in Hand-Held Myometry After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Change From Baseline in Global T2 Relaxation Time of Selected Upper and Lower Limb Muscles After 26 Weeks of Treatment With Deflazacort(Baseline, Week 26)
- Number of Participants With Adverse Events (AEs)(Baseline up to Week 52)
- Area Under the Concentration Curve From Time Zero to t (AUC0-t) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort(Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13)
- Area Under the Concentration Curve From Time Zero to Infinity (AUC0-inf) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort(Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13)
- Maximum Observed Plasma Concentration (Cmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort(Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13)
- Time to Reach Cmax (Tmax) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort(Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13)
- Half-Life (t1/2) of 21-desacetyl Deflazacort and 6β-hydroxy-21-desacetyl Deflazacort(Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Baseline and Week 13)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With GlucocorticoidsSystemic Lupus ErythematosusNCT00082511Genelabs Technologies114
已完成
3 期
A Study of the Safety and Effectiveness of Levofloxacin Compared to Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Skin InfectionsSkin Diseases, BacterialNCT00249197Johnson & Johnson Pharmaceutical Research & Development, L.L.C.413
尚未招募
1 期
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Locally Advanced Unresectable Esophageal Squamous CarcinomaNCT06136988CSPC ZhongQi Pharmaceutical Technology Co., Ltd.129
已完成
2 期
Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)Kidney DiseasesNCT04123613DiaMedica Therapeutics Inc79
招募中
2 期
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCLocally Advanced or Metastatic Breast CancerNCT06439771MediLink Therapeutics (Suzhou) Co., Ltd.180